Table 3. Salvage focal cryotherapy outcomes.

Author	Year	n	Median age (years)	Median pre-salvage PSA (ng/mL)	Median follow-up (months)	Biochemical disease-free survival	Metastasis	Conversion to second-line salvage therapies
Eisenberg and Shinohara (44)	2008	19	71 (avg.)	3.3 (avg.)	18	89% (1 year); 67% (2 years); 50% (3 years)	17.6%	n.a.
De Castro Abreu et al. (38)	2013	25	61	2.8	31	54.4% (5 years)	0%	n.a.
†Wenske et al. (45)	2013	55	66	4	37	47% (5 years); 42% (10 years)	n.a.	n.a.
Bomers et al. (46)	2013	10	67	3.8	12	n.a.	10%	40.0% (focal sCT: 3, ADT: 1)
Li et al. (47)	2015	91	71.1 (avg.)	4.8	15	95.3% (1 year); 72.4% (3 years); 46.5% (5 years)	n.a.	n.a.
Overduin et al. (48)	2017	47	66	4.9	24	51% (1 year)	21.3%	n.a.
Kongnyuy et al. (49)	2017	65	71	4	26.6	48.1% (1 and 3 years)	n.a.	n.a.

^†, primary treatment: RT in 80%, cryotherapy in 20%. RT, radiotherapy; avg., average; n.a., not available; PSA, prostate-specific antigen; ADT, androgen deprivation therapy; sCT, salvage cryotherapy.